Becker Muscular Dystrophy (Genitourinary Disorders) - Drugs In Development, 2021
Summary This latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy - Drugs In Development, 2021, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape.
Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Becker Muscular Dystrophy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3 and 5 respectively.
Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Narcolepsy (Central Nervous System) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Drugs In Development, 2021, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.Narcolepsy is a sleep disorder that...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Sleep Market Report The sleep market by revenue is expected to grow at a CAGR of 6.11% during the period 2020–2026. Several research studies and government programs help improve awareness explaining the importance of sleep in many countries. The...
251 pages •
By Asia Market Information & Development Company
• Aug 2021
China’s demand for Mental Illness Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
Orexin Receptor Type 2 - Drugs In Development, 2021 Summary According to the recently published report ’Orexin Receptor Type 2 - Drugs In Development, 2021’; Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 16 molecules. Out of which approximately...
107 pages •
By Asia Market Information & Development Company
• Aug 2021
This study focuses on China’s Mental Illness Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China...
The global behavioral health software market is expected to reach USD 4.9 billion by 2026 from USD 2.0 billion in 2021, at a CAGR of 19.6% during the forecast period. The major factors driving the growth of behavioral health software are the increasing adoption of behavioral health software, availability of government funding, government initiatives...
Scope of the Report The report titled “Global Psychedelic Drugs Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)”, provides an in depth analysis of the global psychedelic drugs market by value, by indication, etc. The report also provides a detailed analysis of the COVID-19 impact on the psychedelic...
Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020 Summary According to the recently published report ’Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020’; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 12 molecules. Out of...
Narcolepsy - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape. Narcolepsy is a sleep disorder that causes excessive...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.